5 results
To make laquinimod 0.6 mg available for all subjects who completed the placebo-controlled MS-LAQ-301 study according to the protocol and to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in…
Primary: To allow continued use of panobinostat to patients receiving single agent therapy with panobinostat in a Novartis-sponsored study.Secondary: To collect long term data on SAEs.
Primary objective:Pharmacokinetics/-dynamics of 124I-F8IL10 Secondary objective:Dosimetric parameters of arthritic joints and internal organs.
Primary* To compare the disease free survival (DFS) in patients with HL after achieving a complete response following AHSCT with HDT who are treated with panobinostat versus those who receive placebo based on investigator*s review of radiological…
Study whether chloroquine as comedication results in a better respons on Hepatitis B vaccination in non-responder dialysis patients.